+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
ACE Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
ACE Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
New

ACE Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • PDF Icon

    Report

  • 182 Pages
  • November 2025
  • Region: Global
  • TechSci Research
  • ID: 5941813
Free Webex Call
10% Free customization
Description Jump to:

Oral Tablets is the fastest growing segment, North America is the largest regional market

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global ACE Inhibitors Market, valued at USD 6.94 Billion in 2024, is projected to experience a CAGR of 5.75% to reach USD 9.71 Billion by 2030. Angiotensin-converting enzyme (ACE) inhibitors constitute a class of pharmaceutical agents primarily utilized to relax blood vessels and reduce blood pressure, thereby managing conditions such as hypertension, heart failure, and chronic kidney disease. The market for these inhibitors is principally driven by the rising global prevalence of cardiovascular diseases and hypertension, alongside an expanding aging population.

Key Market Drivers

The increasing global burden of cardiovascular diseases represents a fundamental driver for the ACE inhibitors market. The widespread prevalence of conditions such as hypertension and heart failure necessitates effective and accessible therapeutic options. These illnesses not only reduce quality of life but also place substantial strain on healthcare systems worldwide.

According to the "Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023" published in JACC, in September 2025, the number of prevalent cases of cardiovascular disease reached 626 million globally in 2023, underscoring the vast and growing patient population requiring management for these conditions. This elevated disease burden directly fuels the demand for ACE inhibitors, which are cornerstone treatments for various cardiovascular ailments, driving sustained market expansion.

Key Market Challenges

The potential for adverse effects associated with angiotensin-converting enzyme (ACE) inhibitors presents a significant impediment to market expansion. These side effects, including persistent cough, hyperkalemia, and rare angioedema, frequently lead to patient non-adherence or complete discontinuation of therapy. Such reactions directly diminish the patient base that continues to utilize ACE inhibitor treatments. According to research published in *Frontiers in Cardiovascular Medicine* in 2023, approximately 23.0% of patients prescribed ACE inhibitors were non-persistent with their treatment. This substantial rate of non-persistence, often influenced by the challenges of managing adverse drug reactions, directly limits the therapeutic lifespan of ACE inhibitors for individual patients.

Key Market Trends

The growing adoption of fixed-dose combination therapies represents a pivotal trend in the Global ACE Inhibitors Market. These single-pill combinations enhance patient adherence by simplifying complex treatment regimens, which is crucial for managing chronic conditions like hypertension and heart failure. Such formulations improve therapeutic outcomes by ensuring consistent medication intake. For instance, according to a study published in *J Clin Hypertens (Greenwich)* in August 2025, patients receiving angiotensin-converting enzyme inhibitor or angiotensin receptor blocker combination therapies exhibited the highest adherence rate at 79.18% in 2022-2023, compared to other antihypertensive drug classes. This improvement in adherence directly contributes to better disease control and sustained demand for ACE inhibitor-inclusive fixed-dose combinations.

Key Market Players Profiled:

  • Pfizer Inc
  • Novartis AG
  • Johnson & Johnson
  • Merck KGaA
  • Sanofi S.A
  • Bayer AG
  • United Therapeutics Corporation
  • Teva Pharmaceutical Industry
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals Company

Report Scope:

In this report, the Global ACE Inhibitors Market has been segmented into the following categories:

By Type:

  • Sulfhydryl-containing Agents
  • Dicarboxylate-containing Agents.
  • Phosphonate-containing Agents

By Drug:

  • Ramipril
  • Enalapril
  • Benazepril
  • Fosinopril
  • Captopril
  • Moexipril
  • Others

By Dosage Form:

  • Oral Tablets
  • Oral Solutions

By Application:

  • Heart Failure
  • Chronic Kidney Disease
  • Hypertension
  • Diabetes
  • Heart Attack
  • Others

By End user:

  • Hospitals
  • Online Drug Stores
  • Others

By Region:

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global ACE Inhibitors Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global ACE Inhibitors Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents., Phosphonate-containing Agents)
5.2.2. By Drug (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others)
5.2.3. By Dosage Form (Oral Tablets, Oral Solutions)
5.2.4. By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Others)
5.2.5. By End user (Hospitals, Online Drug Stores, Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. North America ACE Inhibitors Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Drug
6.2.3. By Dosage Form
6.2.4. By Application
6.2.5. By End user
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States ACE Inhibitors Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Drug
6.3.1.2.3. By Dosage Form
6.3.1.2.4. By Application
6.3.1.2.5. By End user
6.3.2. Canada ACE Inhibitors Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Drug
6.3.2.2.3. By Dosage Form
6.3.2.2.4. By Application
6.3.2.2.5. By End user
6.3.3. Mexico ACE Inhibitors Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Drug
6.3.3.2.3. By Dosage Form
6.3.3.2.4. By Application
6.3.3.2.5. By End user
7. Europe ACE Inhibitors Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Drug
7.2.3. By Dosage Form
7.2.4. By Application
7.2.5. By End user
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany ACE Inhibitors Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Drug
7.3.1.2.3. By Dosage Form
7.3.1.2.4. By Application
7.3.1.2.5. By End user
7.3.2. France ACE Inhibitors Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Drug
7.3.2.2.3. By Dosage Form
7.3.2.2.4. By Application
7.3.2.2.5. By End user
7.3.3. United Kingdom ACE Inhibitors Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Drug
7.3.3.2.3. By Dosage Form
7.3.3.2.4. By Application
7.3.3.2.5. By End user
7.3.4. Italy ACE Inhibitors Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Drug
7.3.4.2.3. By Dosage Form
7.3.4.2.4. By Application
7.3.4.2.5. By End user
7.3.5. Spain ACE Inhibitors Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Drug
7.3.5.2.3. By Dosage Form
7.3.5.2.4. By Application
7.3.5.2.5. By End user
8. Asia-Pacific ACE Inhibitors Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Drug
8.2.3. By Dosage Form
8.2.4. By Application
8.2.5. By End user
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China ACE Inhibitors Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Drug
8.3.1.2.3. By Dosage Form
8.3.1.2.4. By Application
8.3.1.2.5. By End user
8.3.2. India ACE Inhibitors Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Drug
8.3.2.2.3. By Dosage Form
8.3.2.2.4. By Application
8.3.2.2.5. By End user
8.3.3. Japan ACE Inhibitors Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Drug
8.3.3.2.3. By Dosage Form
8.3.3.2.4. By Application
8.3.3.2.5. By End user
8.3.4. South Korea ACE Inhibitors Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Drug
8.3.4.2.3. By Dosage Form
8.3.4.2.4. By Application
8.3.4.2.5. By End user
8.3.5. Australia ACE Inhibitors Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Drug
8.3.5.2.3. By Dosage Form
8.3.5.2.4. By Application
8.3.5.2.5. By End user
9. Middle East & Africa ACE Inhibitors Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Drug
9.2.3. By Dosage Form
9.2.4. By Application
9.2.5. By End user
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia ACE Inhibitors Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Drug
9.3.1.2.3. By Dosage Form
9.3.1.2.4. By Application
9.3.1.2.5. By End user
9.3.2. UAE ACE Inhibitors Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Drug
9.3.2.2.3. By Dosage Form
9.3.2.2.4. By Application
9.3.2.2.5. By End user
9.3.3. South Africa ACE Inhibitors Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Drug
9.3.3.2.3. By Dosage Form
9.3.3.2.4. By Application
9.3.3.2.5. By End user
10. South America ACE Inhibitors Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Drug
10.2.3. By Dosage Form
10.2.4. By Application
10.2.5. By End user
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil ACE Inhibitors Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Drug
10.3.1.2.3. By Dosage Form
10.3.1.2.4. By Application
10.3.1.2.5. By End user
10.3.2. Colombia ACE Inhibitors Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Drug
10.3.2.2.3. By Dosage Form
10.3.2.2.4. By Application
10.3.2.2.5. By End user
10.3.3. Argentina ACE Inhibitors Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Drug
10.3.3.2.3. By Dosage Form
10.3.3.2.4. By Application
10.3.3.2.5. By End user
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global ACE Inhibitors Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Pfizer Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Novartis AG
15.3. Johnson & Johnson
15.4. Merck KGaA
15.5. Sanofi S.A
15.6. Bayer AG
15.7. United Therapeutics Corporation
15.8. Teva Pharmaceutical Industry
15.9. Bristol-Myers Squibb
15.10. Takeda Pharmaceuticals Company
16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

The companies profiled in this ACE Inhibitors market report include:
  • Pfizer Inc
  • Novartis AG
  • Johnson & Johnson
  • Merck KGaA
  • Sanofi S.A
  • Bayer AG
  • United Therapeutics Corporation
  • Teva Pharmaceutical Industry
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals Company

Table Information

Report AttributeDetails
No. of Pages182
PublishedNovember 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.94 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.71 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

ACE Inhibitors Market Report 2025 - Product Image

ACE Inhibitors Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Angiotensin Converting Enzyme Inhibitors Market - Global Forecast 2025-2032 - Product Image

Angiotensin Converting Enzyme Inhibitors Market - Global Forecast 2025-2032

  • Report
  • 185 Pages
  • Global
From
Zhenju Antihypertensive Tablets Market - Global Forecast 2025-2030 - Product Image

Zhenju Antihypertensive Tablets Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Anti-Hypertensive Drugs - Global Strategic Business Report - Product Image

Anti-Hypertensive Drugs - Global Strategic Business Report

  • Report
  • 293 Pages
  • Global
From
Ace Inhibitors: Market Share, and Growth Analysis by Product Type (Lisinopril, Enalapril, Ramipril, Captopril), Application, End User, Technology - Product Image

Ace Inhibitors: Market Share, and Growth Analysis by Product Type (Lisinopril, Enalapril, Ramipril, Captopril), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.